SavedAdd your journal

Journals / Medicine Science / 2018 / Cilt: 7 - Sayı: 3

Increased serum levels of Bisphenol A and Betatrophin in patients with Psoriasis

SUZAN DEMİR PEKTAŞ
NİGAR YILMAZ
İBRAHİM KIVRAK
Pages
580–586
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bisphenol A and betatrophin may be predictive markers for presence of psoriasis and the disease severity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriasis is a common and serious systemic inflammatory disease.
📊
Key Findings & Data:The purpose of this study is to research the relationship between bisphenol A, betatrophin, urocortin 3 and vitamin D levels in patients with psoriasis.
💡
Conclusion & Impact:Bisphenol A and betatrophin may be predictive markers for presence of psoriasis and the disease severity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Psoriasis is a common and serious systemic inflammatory disease. The purpose of this study is to research the relationship between bisphenol A, betatrophin, urocortin 3 and vitamin D levels in patients with psoriasis. Sixty patients with psoriasis (mean age, 34.1±9.6 years) and twenty six age and gender-matched healthy individuals (mean age, 35.5 ±10.5 years) were included in this study. Bisphenol A, betatrophin, urocortin 3 and vitamin D levels were assessed by using enzyme-linked immunosorbent assay in all participants. Serum levels of bisphenol A were detected using UPLC-ESI-MS/MS. In psoriasis patients, the median bisphenol A serum level was 0.537 ng/mL (range 1.1), and significantly higher compared to controls (median 0.2 range 0.9 ng/mL) (p<0.001). The median serum level of betatrophin was 270 ng/mL (range 5834.7 ng/mL) in patients with psoriasis, and significantly different from the control group (median 198.7, range 198.2). The median serum level of urocortin 3 was 63.3 (range 129.1) in patients with psoriasis, and it was not significantly different compared to control group (median 27 range 537.9). The median serum level of vitamin D was 23.6 (range 377), and it was significantly lower than the control group (median 156.8 range 247.1) (p<0.001). A positive correlation was found between serum bisphenol A and PASI scores in patients with psoriasis (p<0.001, r=0.878). Furthermore, urocortin positively correlated with the duration of illness (p<0.001, r= 0.557). In ROC analysis, bisphenol A values greater than 0.764 were predicted psoriasis with 88.3% sensitivity and 61.5% specificity. Betatrophin levels greater than 0.819 were predicted psoriasis with 80% sensitivity and 69.2% specificity. We have determined a relationship between bisphenol A, betatrophin and vitamin D levels in the inflammatory process in the pathophysiology of psoriasis. Bisphenol A and betatrophin may be predictive markers for presence of psoriasis and the disease severity.

🔖

Cite This Article

PEKTAŞ, S. D., YILMAZ, N., KIVRAK, İ. (2018). Increased serum levels of Bisphenol A and Betatrophin in patients with Psoriasis. Medicine Science, Cilt: 7 - Sayı: 3, 580–586. https://ajindex.com/articles/277263

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Melikoglu M. Sleep Quality and its Association with Disease Severity in Psoriasis. Eurasian J Med. 2017;49:124-7.
  2. Kumar P, James W. Psoriasis, Plaque. StatPearls. Treasure Island. 2017.
  3. Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23:1-6.
  4. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829-35.
  5. Jurgen Schauber, Richard L, Gallo. The vitamin D pathway: a new target for control of the skin’s immune response? Exp Dermatol. 2008;17:633-9.
  6. Crujeiras AB, Zulet MA, Abete I, et al. Interplay of atherogenic factors, protein intake and betatrophin levels in obese-metabolic syndrome patients treated with hypocaloric diets. Int J Obes. 2016;40:403-10.
  7. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18:297-304.
  8. Gisondi P, Galvan A, Idolazzi L, et al. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med. 2015;2:1 Bajaj DR, Mahesar SM, Devrajani BR, et al. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc. 2009;59:512-5.
  9. Mysliwiec H, Baran A, Harasim-Symbor E, et al. Serum fatty acid profile in psoriasis and its comorbidity. Arch Dermatol Res. 2017;309:371-80.
  10. Aytekin A, Togral AK, Yilmaz ÖH. Epoxy Resins and the Relationship with Occupational Dermatoses. Ankara Med J. 2015;15:96-101.
  11. Zangeneh FZ, Fazeli A. The significance of stress hormones in psoriasis. Acta Medica Iranica. 2008;46:485-8.
  12. Singh LK, Boucher W, Pang X, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther. 1999;288:1349-56.
  13. Hannen R, Udeh-Momoh C, Upton J, et al. Dysfunctional Skin-Derived Glucocorticoid Synthesis Is a Pathogenic Mechanism of Psoriasis. J Invest Dermatol. 2017;137:1630-7.
  14. Reich A, Wójcik-Maciejewicz A, Slominski AT. Stress and the skin. G Ital Dermatol Venereol. 2010;145:213-9.
  15. Slominski A, Zbytek B, Nikolakis G,et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013a;137:107-23.
  16. Mehmood ZH, Papandreou D. An updated mini review of vitamin D and obesity: Adipogenesis and inflammation state. Open Access Maced J Med Sci. 2016;4:526–32.
  17. Zhang Y, Leung DY,